From PCOS to PMOS: Why Redefinition of a Common Condition Matters for Women

For decades, millions of women worldwide have been diagnosed with Polycystic Ovary Syndrome (PCOS). However, a significant medical shift occurred in June 2026. Recognizing that the old name was misleading and overly narrow, major medical organizations officially changed the name of the condition to Polyendocrine Metabolic Ovarian Syndrome (PMOS).

This reclassification reflects a deeper, whole-body understanding of a condition that affects much more than reproductive health. In a recent episode of the Baptist HealthTalk podcast, host Sandra Peebles sat down with two Baptist Health experts — obstetrician/gynecologist Ingrid Paredes, M.D., and Priscilla Escalona Villasmil, M.D., endocrinologist — to unpack what this name change means for patients, how the condition is diagnosed, and the long-term metabolic health risks involved.

Beyond the Ovaries: Why the Name Changed to PMOS

The core issue with the name "PCOS" was its hyper-focus on a single organ. Many women who met the hormonal criteria for the condition did not actually display multiple cysts on their ovaries during an ultrasound, leading to mass confusion and delayed care.

"The name change was necessary because the prior one, polycystic ovarian syndrome, would be too focused on the ovaries like the name says,” explains Dr. Paredes. “Many patients will say, 'Okay, I got an ultrasound, I don't have any cyst, so I don't have the syndrome.' So, it was very focused on the ovary — when in reality the syndrome is a condition that is polyendocrine — a metabolic problem that affects the other organ system."

By shifting the medical nomenclature to Polyendocrine Metabolic Ovarian Syndrome, healthcare providers can better signal to patients and the broader medical community that this is a multi-system, systemic condition.

Dr. Villasmil explains how the updated terminology alters the clinical approach from an endocrine perspective:

"The change of the nomenclature is actually leading us, even from the endocrine perspective, to go beyond,” Dr. Villasmil said. “It's actually that this population has an increased risk of metabolic conditions long-term. The recognition of this beyond just the cycle of fertility will actually offer a more multidisciplinary approach for these patients, and early diagnosis as well."

With this broader framework, doctors can identify different "phenotypes" — or variations — of the condition, ensuring that treatment is tailored to the individual rather than a rigid, outdated checklist.

The Root Causes: Hormonal Dysregulation and Insulin Resistance

At its foundation, PMOS stems from a complex neuroendocrine disruption. Hormones managed by the hypothalamus in the brain become dysregulated, which signals the ovaries to overproduce male hormones, known as androgens (such as testosterone).

This hormonal imbalance frequently triggers insulin resistance—a condition where the body's cells do not respond effectively to insulin, forcing the pancreas to pump out excess amounts of the hormone to keep blood sugar stable. Crucially, this metabolic malfunction occurs independently of body weight.

Dr. Escalona Villasmil clarifies that insulin resistance is highly prevalent, even in individuals who do not fit the traditional demographic of being overweight:

"Even patients without obesity that has this condition — they can have increased insulin resistance with hyperinsulinism (when the pancreas makes too much insulin) ... Up to 75 percent of patients with PMOS and a normal weight or a healthy weight, actually have underlying insulin resistance."

This creates a frustrating, cyclical biological loop. The underlying insulin resistance drives up androgen levels, and high androgens make it much easier to gain weight and harder to lose it. This metabolic distress can manifest outwardly in various tissues, causing hair loss on the scalp, heavy hair growth on the face and body, stubborn acne, and specific skin changes.

Symptoms and the "Rotterdam Criteria" for Diagnosis

Because PMOS presents differently in every individual, diagnosis relies on a comprehensive clinical review rather than a single definitive test. Doctors frequently refer to the Rotterdam Criteria, which dictates that a patient must meet at least two out of three specific characteristics to receive a diagnosis:

1. Hyperandrogenism: Signs of elevated male hormones (either through physical symptoms like acne and facial hair growth or confirmed via blood work).
2. Irregular Periods: Infrequent, unpredictable, or absent ovulation.
3. Polycystic Ovaries: The classic "string of pearls" appearance of tiny, undeveloped fluid-filled sacs on an ovarian ultrasound.

Because an ultrasound is not strictly mandatory for every demographic, the diagnostic approach adapts based on a patient’s stage of life.

"If you're in the adolescent area or pre-reproductive years ... we don't even look at the ultrasound. We go mainly on the hormonal aspect," Dr. Paredes notes. "Take a physical history, a history and a physical exam, because there's other features in the physical exam that can point towards it like changes in the skin such as acanthosis nigricans, which is that darkening in the neck usually associated with that insulin resistance."

Furthermore, endocrinologists run extensive laboratory panels to ensure that symptoms are not being caused by a different underlying endocrine disorder. Dr. Escalona Villasmil emphasizes the importance of a meticulous workup:

"We do an extensive hormonal evaluation. There are other hormone conditions that can mimic exactly the same symptoms. So, we rule out thyroid conditions, prolactin (which is the breastfeeding hormone) in cases with period irregularities. And even sometimes ... we go beyond and rule out cortisol excess, like pathological cortisol excess, as a part of the workup and the diagnosis for these patients."

The Fertility Myth: Yes, You Can Get Pregnant

One of the most widespread and damaging pieces of misinformation surrounding this condition is that it guarantees absolute infertility. Many young women receive a diagnosis and assume they cannot conceive, leading to risky contraceptive practices and unexpected situations.

Dr. Paredes strongly dispels this myth, offering a crucial warning to patients:

"It's very important to address that, yes, they can get pregnant. It's more common that I see patients getting pregnant unplanned because they have PCOS than the alternative. Many times, the ones that thought that because they have PCOS cannot get pregnant, and they have an unwanted pregnancy. It's not that they cannot get pregnant, it’s that their ovaries with those multiple cysts, or that abnormality that is happening in the ovary, doesn't allow the regular ovulation to happen."

Because ovulation is irregular or infrequent, the window for conception is simply harder to track. When a patient is actively trying to conceive, doctors can safely induce regular ovulation using medications.

"I can give them a pill that will get them to ovulate, and it's called letrozole," Dr. Paredes explains. "There's different ovulation induction medications. There were studies done that patients that have PCOS do better to be able to get pregnant with letrozole, compared to Clomid ... I have more patients that have delivered babies with PCOS than patients with PCOS going through infertility."

However, the medical team notes that once a pregnancy is achieved, continued monitoring is essential. The systemic nature of PMOS carries over into pregnancy, increasing the baseline risk for developing gestational diabetes and pregnancy-induced high blood pressure.

Long-Term Whole-Body Health Risks

While irregular periods and cosmetic symptoms like facial hair are the most immediate concerns for younger patients, the long-term metabolic risks of PMOS require lifelong, proactive management. If left unmanaged, chronic insulin resistance and hormonal imbalances can pave the way for severe medical conditions later in life.

Dr. Escalona Villasmil outlines the serious vascular and metabolic threats associated with the syndrome:

"There is increased risk of diabetes. (With) any kind of glucose metabolism abnormality, hypertension, there is increased risk of cardiovascular disease. Even in this population, there is an increased risk of heart attacks and even a stroke, compared to general population or women without PC—PMOS."

Additionally, having chronically irregular periods means the uterine lining (endometrium) does not shed as frequently as it should. This buildup of tissue raises the long-term risk of endometrial hyperplasia—a condition characterized by an overgrowth of cells that can eventually progress to uterine cancer if untreated. Because of these cumulative risks, managing the condition through lifestyle changes and medical therapies is vital.

Treatment Pathways: Lifestyle, Hormones, and Modern Therapeutics

There is currently no absolute cure for PMOS, but the condition is highly manageable. Because it involves both reproductive and metabolic pathways, a dual approach combining gynecology and endocrinology yields the most effective results.

1. Lifestyle Interventions

Both specialists agree that lifestyle modifications remain the foundational baseline of any treatment protocol. Modest weight loss can profoundly alter a patient’s hormonal profile.

"Lifestyle interventions on these patients are critically important, especially when they're looking to get pregnant," says Dr. Escalona Villasmil. "If you keep a healthy weight, and we work on weight loss, definitely the odd of insulin resistant will improve, the androgen secretion will improve, and we even have patients that they can have normal menses (menstrual period) without the support of birth control pills. Even 10 percent of the weight [loss] can actually trigger ovulation."

2. Hormonal and Anti-Androgen Medications

To regulate the uterine lining and address cosmetic symptoms like severe acne and hirsutism (excessive hair growth), standard medical options are frequently utilized. Dr. Paredes explains the mechanics behind oral contraceptives:

"Typical treatment options are birth control pills ... The way they would potentially help is that they increase the sex hormone binding globulin in the liver, which would then bind to this free testosterone that is in the blood — therefore decreasing the physiologic appearance of the PCOS. If you decrease the testosterone, there's less hirsutism."

For targeted anti-hair growth therapy, doctors may add spironolactone, a medication that acts as a testosterone receptor blocker. However, Dr. Escalona Villasmil notes an essential safety caveat:

"This medication works as an anti-androgen. We need to use it along with birth control pills and contraception because we cannot — women should not get pregnant on this medication because of the babies and the teratogenicity [risk of birth defects] related to it."

3. Insulin Sensitizers and Weight-Loss Medications

To combat underlying metabolic dysfunction, metformin is widely prescribed to improve insulin sensitivity and support cycle regularity.

"It will improve... it's an important and powerful insulin sensitizer," Dr. Escalona Villasmil explains. "It can even help up to 50 percent of women without birth control pills. They can achieve regularization of the menses (menstrual period) with metformin in the background."

The modern therapeutic landscape has also been revolutionized by GLP-1 receptor agonists, such as semaglutide and tirzepatide. Originally designed for type 2 diabetes and obesity management, these medications are showing profound promise in breaking the cycle of insulin resistance in PMOS patients.

Dr. Escalona Villasmil points out that these newer agents are an incredibly valuable addition for patients dealing with severe obesity, with significant ongoing clinical research exploring their direct utility in managing PMOS.

Looking Ahead: Advocacy, Funding, and Early Action

The clinical community is highly optimistic that the transition from "PCOS" to "PMOS" will unlock vital structural benefits for patient care, particularly regarding medical insurance coverage and scientific research funding. Historically, many treatments—including advanced weight-management therapies—were denied by insurance providers because the condition was categorized strictly as a fertility or reproductive issue.

By validating PMOS as a chronic metabolic condition, researchers hope to secure federal grants to investigate the root neuroendocrine pathways in the brain that trigger the syndrome in the first place, potentially opening the door for novel, targeted therapies.

Ultimately, the most critical takeaway for any health consumer is to seek early medical guidance without fear. PMOS is entirely manageable, and taking proactive control of your metabolic health today protects your cardiovascular and reproductive well-being for tomorrow.